Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Novartis Ag ADR
(NY:
NVS
)
102.57
-0.12 (-0.12%)
Official Closing Price
Updated: 7:00 PM EDT, May 17, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Novartis Ag ADR
< Previous
1
2
...
28
29
30
31
32
33
34
35
36
...
38
39
Next >
The Week Ahead In Biotech (Sept. 19-25): Incyte, Verrica FDA Decisions And Conference Presentations In The Spotlight
September 19, 2021
Biotech stocks declined for the week ending Sept. 17, extending the losses from the previous week. European Society for Medical Oncology presentations, vaccine news, clinical...
Via
Benzinga
Exposures
Product Safety
Visualizing the World’s Biggest Pharmaceutical Companies
September 17, 2021
Some of the world’s biggest pharmaceutical companies have played a central role in the COVID-19 pandemic.
Via
Talk Markets
Exposures
COVID-19
Novartis' Prostate Cancer Therapy Linked To Improved Quality Of Life
September 17, 2021
Novartis AG (NYSE: NVS) is building the case for its radioligand therapy, 177Lu-PSMA-617. With positive Phase 3 primary endpoint data in the bag, Novartis at the European...
Via
Benzinga
Zymeworks' Zanidatamab Aces Mid-Stage Esophageal Cancer Trial
September 16, 2021
At the European Society of Medical Oncology Congress 2021 (ESMO21), Zymeworks Inc (NYSE: ZYME) presented encouraging early data on its HER2‑targeted bispecific antibody. Twenty-...
Via
Benzinga
What may be behind achy, tired, or burning eyes? Dry eye disease may be the culprit.
September 09, 2021
(BPT) - Sponsored by Novartis Pharmaceuticals Corporation.
Via
Brandpoint
Exposures
COVID-19
Better Pharmaceutical Stock: Apellis or Novartis?
September 15, 2021
The pharmaceutical industry is expected to remain in the limelight as companies race to develop new medicines catering to mild diseases and critical ailments.
Via
Talk Markets
CureVac Shares Fall After Cutting COVID-19 Vaccine Production Plans
September 14, 2021
CureVac BV has canceled contract manufacturing deals for its experimental COVID-19 vaccine with two prospective partners.
Via
Talk Markets
Exposures
COVID-19
CureVac Shares Fall After Cutting COVID-19 Vaccine Production Plans
September 14, 2021
CureVac BV (NASDAQ: CVAC) has canceled contract manufacturing deals for its experimental COVID-19 vaccine with two prospective partners. The Company would...
Via
Benzinga
Exposures
COVID-19
Regenerative Medicine Market Growing at a CAGR of 15.9% – Rising Demand for Organ Transplantations
September 14, 2021
The global regenerative medicine market is expected to reach USD 17.9 billion by 2025 from USD 8.5 billion in 2020, at a CAGR of 15.9%.
Via
SBWire
Exposures
Product Safety
Why Regenxbio Stock Is Way Up Today
September 13, 2021
American biopharmaceutical giant AbbVie wants access to Regenexbio's gene therapy for macular degeneration.
Via
The Motley Fool
ADHD Drug Developer Cingulate Plans NASDAQ Debut
September 10, 2021
Cingulate Inc filed for an IPO, penciling in a modest $58 million raise, and expects to list on NASDAQ under CING ticker. Cingulate has a Phase 3-ready attention...
Via
Benzinga
Topics
Initial Public Offering
Exposures
Securities Market
Why Did Wedbush Downgrade Xoma?
September 07, 2021
Wedbush has cut XOMA Corporation (NASDAQ: XOMA) to neutral from outperform and lowered its price target to $22 from $41. Analyst Liana Moussatos notes ...
Via
Benzinga
DGTL is First Enabled to Convert and Distribute Social Media Influencer Content to Programmatic Web Ads
September 07, 2021
New York, New York--(Newsfile Corp. - September 7, 2021) - DGTL Holdings Inc. (TSXV: DGTL) (OTCQB: DGTHF) (FSE: A2QB0L) ("DGTL"...
Via
Newsfile
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Novartis Stops Iscalimab Trial In Kidney Transplant Patients
September 03, 2021
Novartis AG (NYSE: NVS) has halted a Phase 2 trial of CFZ533 (iscalimab) in kidney transplant patients. The decision follows interim data that showed iscalimab was...
Via
Benzinga
Price Over Earnings Overview: Novartis
September 02, 2021
Looking into the current session, Novartis Inc. (NYSE:NVS) is trading at $92.23, after a 0.45% drop. Over the past month, the stock decreased by 0.02%, but over the...
Via
Benzinga
The Rising Delta Variant
September 01, 2021
China is not only cracking down on kiddie playtime. It also is absorbing bankruptcy claims from real estate developer Evergrande.
Via
Talk Markets
Topics
Bankruptcy
Exposures
Financial
Legal
Coherra Continue to Add Strength to the Organization and Cap Table With the Appointment of Thomas Ebeling as a New Member of the Advisory Board
September 01, 2021
Coherra is strengthening its global business development ahead of the scaling phase with the appointment of Thomas Ebeling as Advisory Board Member. Thomas will be working with Coherra's founder, Søren...
Via
Newswire.com
Novartis, NHS England Ink Access Deal For Cholesterol Drug Leqvio
September 01, 2021
The U.K. government, NHS England, and Novartis AG (NYSE: NVS) unveiled a "world-first" reimbursement deal for providing broader access to anti-cholesterol...
Via
Benzinga
DGTL Holdings Inc. Reports the Completion of Software Development for Hashoff 2.0
August 31, 2021
New York, New York--(Newsfile Corp. - August 31, 2021) - DGTL Holdings Inc. (TSXV: DGTL) (OTCQB: DGTHF) (FSE: D0G) (WKN:...
Via
Newsfile
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Vision Care Products Market Giants Spending Is Going to Boom with CooperVision, Essilor International S.A., Carl Zeiss Meditec
August 30, 2021
Vision Care Products Comprehensive Study by Type (Eye Glasses (Single Vision Eyeglasses, Bifocal Eyeglasses, Progressive Eyeglasses), Contact Lens (Personalized/Custom, Specific Care, Single Vision,...
Via
SBWire
The Daily Biotech Pulse: MorphoSys-Incyte Snag European Nod, Immutep Granted Chinese Patent, Bolt Biotherapeutics Strike Oncology Collaboration
August 27, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 26) Agenus Inc. (NASDAQ: AGEN)...
Via
Benzinga
Topics
Intellectual Property
Exposures
Intellectual Property
UCB Gets EU Approval For Bimekizumab In Psoriasis
August 25, 2021
The European Commission has cleared UCB's (OTC: UCBJF) Bimzelx (bimekizumab) for moderate to severe plaque psoriasis in adults. UCB's confidence lies in...
Via
Benzinga
Living with Chronic Hives: One Woman’s Story
August 25, 2021
(BPT) - Ilana, a board-certified emergency medicine physician, lived with chronic hives for almost as long as she can remember. 'I've had them since I was at least 8 years old,' she says. 'It's...
Via
Brandpoint
Exposures
Product Safety
The Daily Biotech Pulse: Lilly Strikes $1.6B R&D Collaboration, FSD Pulls Plug On COVID-19 Program, Cassava Sinks On Questions About Alzheimer's Drug
August 25, 2021
ere's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 24) Agenus Inc. (NASDAQ: AGEN)...
Via
Benzinga
Exposures
COVID-19
Novartis' STAMP Inhibitor Under FDA Review For Myeloid Leukemia
August 25, 2021
The FDA has accepted for review Novartis AG's (NYSE: NVS) marketing application seeking approval for asciminib (ABL001) in chronic myeloid leukemia (CML)....
Via
Benzinga
Exposures
Product Safety
Reuters Events Announces the Shortlist for the 12th Annual Responsible Business
August 25, 2021
SOURCE: Reuters Events Sustainable Business
Via
3BL Media
Topics
Emissions
Stocks
Exposures
COVID-19
US Equities
Only The Conservative Pot Stocks Index Is Up YTD And Currently Yields 4.9%
August 25, 2021
If you were to invest in a basket of the major companies that have bought into marijuana companies you could possibly generate greater returns than only owning the associated marijuana company.
Via
Talk Markets
Topics
Cannabis
Exposures
Cannabis
Novartis's Kymriah Flunks In Late-Stage NHL Study
August 24, 2021
Novartis AG's (NYSE: NVS) Kymriah (tisagenlecleucel) CAR-T therapy failed to meet its primary endpoint of event-free survival in a Phase 3 study in aggressive...
Via
Benzinga
Now That The FDA Approved Pfizer-BioNTech, Is This It For Vaccine Stocks?
August 23, 2021
If there's one thing to take away from any conversation about biotech stocks, it's that any company with their hat in the ring is likely making a version of something they hope to be better than the...
Via
Talk Markets
Exposures
Product Safety
The Daily Biotech Pulse: Cara's Korsuva Greenlighted By FDA, Clinical Trial Disappointments For Novartis, Theravance, Vertex Inks CRISPR Licensing Deal
August 24, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 23) AbbVie Inc. (NYSE: ABBV) (...
Via
Benzinga
Exposures
Product Safety
< Previous
1
2
...
28
29
30
31
32
33
34
35
36
...
38
39
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.